Gastrointestinal adverse events · preventing acute otitis media in children up to 12 years of age
Xylitol showed no clear difference in gastrointestinal‐related adverse events compared with control (moderate certainty).
3 findings from 1 review
RR 1.04 [0.92, 1.16]
1 study · 326 participants
Moderate
RR 1.43 [0.74, 2.75]
3 studies · 1826 participants
Moderate
RR 2.82 [0.61, 13]
1 study · 1277 participants
Moderate
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · general population and healthcare workers
1 finding from 1 review
Adverse events · general population
1 finding from 1 review
Adverse events · general population and healthcare workers
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
Homeopathic medicinal products (individualised treatment) showed no clear difference in adverse events compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Adverse events · children (0 to 24 months)
Palivizumab showed no clear difference in adverse events compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Adverse events · children up to age 18 years
Probiotic showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · susceptible children exposed to measles
1 finding from 1 review
Adverse events · susceptible people exposed to measles
1 finding from 1 review
Adverse events ‐ short term · people suspected to have meningococcal disease (adults and children)
1 finding from 1 review
Adverse events ‐ not measured · susceptible people exposed to rubella
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of skin adverse events · children (age < 18 years) susceptible to acute respiratory tract infections (ARTIs)
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of gastrointestinal adverse events · children (age < 18 years) susceptible to acute respiratory tract infections (ARTIs)
1 finding from 1 review
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ isoniazid prophylaxis only (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review